XBiotech (XBIT) Common Equity (2014 - 2026)
XBiotech (XBIT) posted quarterly Common Equity of $140.4 million for Q4 2025, down 23.0% year-over-year from $182.3 million in Q4 2024, and down 16.0% quarter-over-quarter from $167.1 million in Q3 2025.
XBiotech (XBIT) Common Equity (2014 - 2026) Analysis & Trends
XBiotech's Common Equity history runs 12 years deep, the most recent figure standing at $140.4 million for Q4 2025.
- In Q4 2025, Common Equity fell 23.0% year-over-year to $140.4 million; the TTM figure through Dec 2025 stood at $140.4 million (down 23.0% YoY), while the FY2025 annual figure was $140.4 million, down 23.0% from the prior year.
- Common Equity for Q4 2025 stood at $140.4 million, down from $167.1 million in the prior quarter.
- The five-year high for Common Equity was $352.1 million in Q1 2021, with the low at $140.4 million in Q4 2025.
- The 5-year median for Common Equity is $225.9 million (2023), against an average of $229.7 million.
- The sharpest annual moves came in 2021 and 2022: Common Equity rose 1.45% in 2021, then declined 26.61% in 2022.
- XBiotech's Common Equity stood at $269.4 million in 2021, then decreased by 10.76% to $240.4 million in 2022, then declined by 8.97% to $218.8 million in 2023, then slipped by 16.71% to $182.3 million in 2024, then fell by 23.0% to $140.4 million in 2025.
- Business Quant data shows XBIT's Common Equity at $140.4 million in Q4 2025, $167.1 million in Q3 2025, and $173.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | XBiotech | 68.90 Mn | 68.90 Mn | - | 128.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 128.46 Mn |
| Dec 31, 2025 | 140.35 Mn |
| Sep 30, 2025 | 167.08 Mn |
| Jun 30, 2025 | 173.06 Mn |
| Mar 31, 2025 | 174.71 Mn |
| Dec 31, 2024 | 182.27 Mn |
| Sep 30, 2024 | 192.12 Mn |
| Jun 30, 2024 | 196.70 Mn |
| Mar 31, 2024 | 209.28 Mn |
| Dec 31, 2023 | 218.85 Mn |
| Sep 30, 2023 | 222.66 Mn |
| Jun 30, 2023 | 229.06 Mn |
| Mar 31, 2023 | 236.91 Mn |
| Dec 31, 2022 | 240.40 Mn |
| Sep 30, 2022 | 244.81 Mn |
| Jun 30, 2022 | 255.80 Mn |
| Mar 31, 2022 | 265.56 Mn |
| Dec 31, 2021 | 269.39 Mn |
| Sep 30, 2021 | 274.16 Mn |
| Jun 30, 2021 | 348.56 Mn |